scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, chief executive officer, will present at the following investor conferences in June:

Does scPharmaceuticals Inc. (NASDAQ:SCPH) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]

BURLINGTON, Mass., Nov. 14, 2019 -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential.

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission  Company.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the first quarter ended March 31, 2020 and provided a business update.

Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned.

Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and.

BURLINGTON, Mass., Aug. 06, 2019 -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.

scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

What happened Shares of scPharmaceuticals (NASDAQ: SCPH) have plunged today, down by 22% as of 1 p.m. EDT, after the company announced the pricing of a public secondary offering. The deal priced at $8.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 5,780,347 shares of its common stock at a public offering price of $8.65 per share, before deducting underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $50.0 million. All shares of common stock to be sold in the offering are being offered by scPharmaceuticals. The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 867,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 26, 2020, subject to customary closing conditions.

Anyone researching scPharmaceuticals Inc. (NASDAQ:SCPH) might want to consider the historical volatility of the share...

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by scPharmaceuticals. In addition, the underwriters will have a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price less the underwriting discount. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Every investor in scPharmaceuticals Inc. (NASDAQ:SCPH) should be aware of the most powerful shareholder groups...